|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan显示文摘AIM:To evaluate the efficacy and safety of esomeprazole-based triple therapy compared with lansoprazole therapy as first-line eradication therapy for patients with Helicobacter pylori(H.pylori)in usual post-marketing use in Japan,where the clarithromycin(CAM)resistance rate is 30%.METHODS:For this multicenter,randomized,openlabel,non-inferiority trial,we recruited patients(≥20years of age)with H.pylori infection from 20 hospitals in Japan.We randomly allocated patients to esomeprazole therapy(esomeprazole 20 mg,CAM 400 mg,amoxicillin(AC)750 mg for the first 7 d,with all drugs given twice daily)or lansoprazole therapy(lansoprazole30 mg,CAM 400 mg,AC 750 mg for the first 7 d,with all drugs given twice daily)using a minimization method with age,sex,and institution as adjustment factors.Our primary outcome was the eradication rate by intention-to-treat(ITT)and per-protocol(PP)analyses.H.pylori eradication was confirmed by a urea breath test from 4 to 8 wk after cessation of therapy.RESULTS:ITT analysis revealed the eradication rates of 69.4%(95%CI:61.2%-76.6%)for esomeprazole therapy and 73.9%(95%CI:65.9%-80.6%)for lansoprazole therapy(P=0.4982).PP analysis showed eradication rate of 76.9%(95%CI:68.6%-83.5%)for esomeprazole therapy and 79.8%(95%CI:71.9%-86.0%)for lansoprazole therapy(P=0.6423).There were no differences in adverse effects between the two therapies.CONCLUSION:Esomeprazole showed non-inferiority and safety in a 7 day-triple therapy for eradication of H.pylori compared with lansoprazole. | Tsutomu Nishida Masahiko Tsujii Hirohisa Tanimura Shusaku Tsutsui Shingo Tsuji Akira Takeda Atsuo Inoue Hiroyuki Fukui Toshiyuki Yoshio Osamu Kishida Hiroyuki Ogawa Masahide Oshita Ichizo Kobayashi Shinichiro Zushi Makoto Ichiba Naoto Uenoyama Yuichi Yasunaga Ryu Ishihara Mamoru Yura Masato Komori Satoshi Egawa Hideki Iijima Tetsuo Takehara | 2014 | World Journal of Gastroenterology2014，20，15： | 13 |
| 2 | Usefulness of urinary trypsinogen-2 and trypsinogen activation peptide in acute pancreatitis:A multicenter study in Japan显示文摘BACKGROUND Rapid urinary trypsinogen-2 dipstick test and levels of urinary trypsinogen-2 and trypsinogen activation peptide(TAP) concentration have been reported as prognostic markers for the diagnosis of acute pancreatitis.AIM To reconfirm the validity of all these markers in the diagnosis of acute pancreatitis by undertaking a multi-center study in Japan.METHODS Patients with acute abdominal pain were recruited from 17 medical institutions in Japan from April 2009 to December 2012. Urinary and serum samples were collected twice, at enrollment and on the following day for measuring target markers. The diagnosis and severity assessment of acute pancreatitis were assessed based on prognostic factors and computed tomography(CT) Grade of the Japanese Ministry of Health, Labour, and Welfare criteria.RESULTS A total of 94 patients were enrolled during the study period. The trypsinogen-2 dipstick test was positive in 57 of 78 patients with acute pancreatitis(sensitivity,73.1%) and in 6 of 16 patients with abdominal pain but without any evidence of acute pancreatitis(specificity, 62.5%). The area under the curve(AUC) score of urinary trypsinogen-2 according to prognostic factors was 0.704, which was highest in all parameter. The AUC scores of urinary trypsinogen-2 and TAP according to CT Grade were 0.701 and 0.692, respectively, which shows higher than other pancreatic enzymes. The levels of urinary trypsinogen-2 and TAP were significantly higher in patients with extended extra-pancreatic inflammation as evaluated by CT Grade.CONCLUSION We reconfirmed urinary trypsinogen-2 dipstick test is useful as a marker for the diagnosis of acute pancreatitis. Urinary trypsinogen-2 and TAP may be considered as useful markers to determine extra-pancreatic inflammation in acute pancreatitis. | Hiroaki Yasuda Keisho Kataoka Yoshifumi Takeyama Kazunori Takeda Tetsuhide Ito Toshihiko Mayumi Shuji Isaji Tetsuya Mine Motoji Kitagawa Seiki Kiriyama Junichi Sakagami Atsushi Masamune Kazuo Inui Kenji Hirano Ryukichi Akashi Masamichi Yokoe Yoshio Sogame Kazuichi Okazaki Chie Morioka Yasuyuki Kihara Shigeyuki Kawa Masao Tanaka Akira Andoh Wataru Kimura Isao Nishimori Junji Furuse Isao Yokota Tooru Shimosegawa | 2019 | World Journal of Gastroenterology2019，25，1： | 7 |
| 3 | Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B显示文摘AIM To evaluate the diagnostic performance of angiotensinconverting enzyme(ACE)on significant liver fibrosis in patients with chronic hepatitis B(CHB). METHODS In total,100 patients with CHB who underwent liver biopsy in our hospital were enrolled,and 70 patients except for 30 patients with hypertension,fatty liver or habitual alcoholic consumption were analyzed.We compared histological liver fibrosis and serum ACE levels and evaluated the predictive potential to diagnose significant liver fibrosis by comparison with several biochemical marker-based indexes such as the aspartate aminotransferase(AST)-to-platelet ratio index(APRI),the fibrosis index based on four factors(FIB-4),the Mac-2 binding protein glycosylation isomer(M2BPGi)level and the number of platelets(Plt). RESULTS Serum ACE levels showed moderately positive correlation with liver fibrotic stages(R2=0.181).Patients with significant,advanced fibrosis and cirrhosis(F2-4)had significantly higher serum ACE levels than those with early-stage fibrosis and cirrhosis(F0-1).For significant fibrosis(≥F2),the 12.8 U/L cut-off value of ACE showed 91.7%sensitivity and 75.0%specificity.The receiver-operating characteristic(ROC)curves analysis revealed that the area under the curve(AUC)value of ACE was 0.871,which was higher than that of APRI,FIB-4,M2BPGi and Plt. CONCLUSION The serum ACE level could be a novel noninvasive,easy,accurate,and inexpensive marker of significant fibrosis stage in patients with CHB. | Ryuichi Noguchi Kosuke Kaji Tadashi Namisaki Kei Moriya Mitsuteru Kitade Kosuke Takeda Hideto Kawaratani Yasushi Okura Yosuke Aihara Masanori Furukawa Akira Mitoro Hitoshi Yoshiji | 2017 | World Journal of Gastroenterology2017，23，36： | 6 |
| 4 | TLR signaling pathways显示文摘 | Kiyoshi Takeda Shizuo Akira | 2003 | Seminars in Immunology2003，，1： | 4 |
| 5 | TOLL-LIKE RECEPTORS显示文摘 | Kiyoshi Takeda Tsuneyasu Kaisho Shizuo Akira | 2003 | Annual Review of Immunology2003，，： | 2 |
| 6 | Microbial recognition by Toll-like receptor 显示文摘 | Takeda K Akira S | 2004 | J Dermatol Sci2004，34，2： | 1 |
| 7 | Toll-like receptors显示文摘 | Takeda K Kaisho T Akira S | 2003 | Annu rev im- munol2003，21，1： | 1 |
| 8 | Toll-like receptors:critical proteins linking innate and acquired immunity显示文摘 | Akira S Takeda K Kaisho T | 2001 | Nat Immunol2001，2，8： | 1 |
| 9 | STAT family of transcription factors in cytokinemediated biological responses 显示文摘 | Takeda K Akira S | 2000 | Cytokine Growth Factor Rev2000，11，： | 1 |
| 10 | Toll-like receptors in innate immunity显示文摘 | Takeda K Akira S | 2005 | Int Immunol2005，17，1： | 1 |
| 11 | Toll-like receptors:criticalproteins linking innate andacquired immunity 显示文摘 | Akira S Takeda K Kaisho T | 2001 | Nat Immunol2001，2，8： | 1 |
| 12 | Toll-like receptor signalling显示文摘 | Akira S Takeda K | 2004 | Na- ture Reviews Immunology2004，4，7： | 1 |
| 13 | Toll-like receptors显示文摘 | Takeda K Kaisho T Akira S | 2003 | Annu Rev Im- munol2003，21，： | 1 |
| 14 | STAT family of transcription factors in cytokinemediated biological responses 显示文摘 | Takeda K Akira S | 2000 | Cytokine Growth Factor Rev2000，11，3： | 1 |
| 15 | Toll-like receptors显示文摘 | Takeda K Kaisho T Akira S | 2003 | Annu Rev Immunol2003，21，： | 1 |
| 16 | TolMike receptor signalling显示文摘 | Akira S Takeda K | 2004 | Nat Rev Immunol2004，4，7： | 1 |
| 17 | Toll-like receptor sibaalling显示文摘 | Takeda K | 2004 | Nat Rev lmmunol2004，4，7： | 1 |
| 18 | Toll- like receptors显示文摘 | Takeda K Kaisho T Akira S | 2003 | Annu Rev Immunol2003，21，： | 1 |
| 19 | TLR signaling pathways显示文摘 | Takeda K Akira S | 2004 | Seminars in Immunolgy2004，16，： | 1 |
| 20 | Tou-like recentors显示文摘 | Takeda K Kalsho T Akira S | 2003 | Annu Rev lmmunol2003，21，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员